Noah Medical's Galaxy surgical robot system has made its debut in Asia with the first clinical trial conducted at Prince of Wales Hospital in Hong Kong. This marks a significant milestone for the San Carlos, California-based company, which received FDA clearance for the Galaxy system in March. Designed to enhance bronchoscopic visualisation and access, the system incorporates advanced imaging technologies for real-time updates on potential cancerous lesions. The trial in Hong Kong, led by Dr. Calvin Ng and Dr. Rainbow Lau, aims to validate the system's accuracy, diagnostic yield, and overall effectiveness in conducting robotic bronchoscopies.
The Galaxy system, boasting proprietary integrated tomosynthesis (TiLT+ Technology) with augmented fluoroscopy, offers a disposable, single-use bronchoscope and a compact footprint for easy integration into bronchoscopy suites. The technology's focus is on improving tool-in-lesion capabilities and diagnostic accuracy, allowing physicians to confidently navigate and biopsy lung nodules. Noah Medical anticipates that the trial in Hong Kong will contribute valuable insights and further validate the efficacy of its TiLT+ Technology, paving the way for enhanced early diagnosis and treatment of lung cancer not only in Hong Kong but across the broader Asian region.
Jian Zhang, Noah Medical's founder and CEO, expressed excitement about the collaboration with Prince of Wales Hospital, emphasising the company's mission to support physicians in diagnosing and treating lung cancer more accurately and efficiently. The successful enrollment of the first patients and the ongoing trial signify a crucial step in advancing robotic lung technologies in Asia, with the potential to benefit billions of patients globally.
Click here to read the original news story.